comparemela.com

Latest Breaking News On - Abecma - Page 1 : comparemela.com

FDA Approves Ide-Cel for Triple-Class Exposed R/R Multiple Myeloma

The FDA has approved ide-cel (Abecma) for adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy.

Immune Engager Therapies Demonstrate Promise Following Relapse on Ide-Cel in Multiple Myeloma

Treatment with immune engager therapies following relapse on ide-cel resulted in better median PFS vs other therapies for patients with multiple myeloma.

Idecabtagene Vicleucel Approaches EU Approval in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

Ecma: Four to five years is the required development period for BS VII , ET Auto

In the global trend of increasingly stringent emission norms, Euro 7, proposed for enforcement in light duty vehicles from July 2025, will set a new record. India has been following Europe for its emission regulations. In this exclusive interview, President, ECMA (an industry Body exclusively for emission control technology suppliers in India), and Head – Commercial, BASF Catalysts India, Harindranath Revanur, discusses with ETAuto’s Sumantra Bibhuti Barooah about BSVII, how easy or challenging the shift could be, and the growing scope of ECMA.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.